<DOC>
	<DOCNO>NCT01203631</DOCNO>
	<brief_summary>This trial conduct Europe North America . The aim trial assess disease activity safety subject moderately severely active Crohn 's disease ( CD ) treat NNC 0142-0000-0002 .</brief_summary>
	<brief_title>Safety Efficacy NNC 0142-0000-0002 Subjects With Moderately Severely Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects CD least 3 month Subjects treat , subject either respond treatment , respond lose response continue administration therapeutic compound Any following : Symptomatic bowel obstruction , short bowel syndrome , ileostomy colostomy , surgical bowel resection within 6 month prior randomisation clinically relevant undrained abscess History dysplasia malignancy colon Any ongoing chronic active infectious disease microbial infection require systemic oral intravenous treatment infection within 1 month prior randomisation Body mass index ( BMI ) high equal 38.0 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>